13D Filing: Lansdowne Partners and Summit Therapeutics PLC (ADR) (SMMT)

Page 6 of 8 – SEC Filing

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

(a – e) Regarding
aggregate beneficial ownership, see Row 11 of the cover page of each Reporting Person. Regarding percentage beneficial ownership,
see Row 13 of the cover page of each Reporting Person. Regarding sole power to vote shares, see Row 7 of the cover page of each
Reporting Person. Regarding shared power to vote shares, see Row 8 of the cover page of each Reporting Person. Regarding sole power
to dispose of shares, see Row 9 of the cover page of each Reporting Person. Regarding shared power to dispose of shares, see Row
10 of the cover page of each Reporting Person.

There have been
no transactions by the Reporting Persons in the Shares during the past sixty days.

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

None

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

Exhibit A

Exhibit B

Joint Filing Agreement

Schedule of Transactions in Shares

Follow Summit Therapeutics Inc. (NASDAQ:SMMT)